Gravity Analytica

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

ARCT 10.31.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-07

Name of Upcoming Event:Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call

Full Press Release SEC Filings Our ARCT Tweets

About Gravity Analytica

Recent Filings

PDF Version

SAN DIEGO--(BUSINESS WIRE)--Oct. 31, 2024--Arcturus Therapeutics Holdings Inc.(the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter endedSeptember 30, 2024after the market close onThursday, November 7and will also host a conference call and webcast at4:30 pm Eastern TimeonNovember 7, 2024.

Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call

Thursday, November 7, 2024@4:30 p.m. ET
Domestic: 1-800-274-8461
International: 1-203-518-9814
Conference ID: ARCTURUS
Webcast:Link

About Arcturus

Founded in 2013 and based inSan Diego, California,Arcturus Therapeutics Holdings Inc.(Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE^®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture inJapan,ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in theU.S.,Europe,Japan,China, and other countries). For more information, visitwww.ArcturusRx.com. In addition, please connect with us onTwitterandLinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241031211431/en/

IR and Media ContactsArcturus TherapeuticsNeda SafarzadehVP, Head of IR/PR/MarketingIR@arcturusrx.com

Source:Arcturus Therapeutics Holdings Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com